company background image
3320 logo

China Resources Pharmaceutical Group SEHK:3320 Stock Report

Last Price

HK$5.16

Market Cap

HK$32.4b

7D

-0.6%

1Y

-25.1%

Updated

18 Mar, 2024

Data

Company Financials +

China Resources Pharmaceutical Group Limited

SEHK:3320 Stock Report

Market Cap: HK$32.4b

3320 Stock Overview

China Resources Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and Hong Kong.

3320 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth3/6
Past Performance2/6
Financial Health3/6
Dividends2/6

China Resources Pharmaceutical Group Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for China Resources Pharmaceutical Group
Historical stock prices
Current Share PriceHK$5.16
52 Week HighHK$8.13
52 Week LowHK$4.45
Beta0.36
1 Month Change0.98%
3 Month Change9.55%
1 Year Change-25.11%
3 Year Change-2.46%
5 Year Change-52.49%
Change since IPO-42.73%

Recent News & Updates

China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon

Jan 28
China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon

We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt

Dec 06
We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt

Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?

Sep 07
Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?

Recent updates

China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon

Jan 28
China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon

We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt

Dec 06
We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt

Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?

Sep 07
Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?

Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?

Aug 02
Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?

With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case

May 26
With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case

These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

May 05
These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year

Apr 04
China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year

Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?

Jan 24
Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?

Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?

Dec 15
Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?

China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price

Oct 18
China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price

China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt

Aug 27
China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt

China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15

May 29
China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15

May 02
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15

China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's

Apr 07
China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's

China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet

Mar 31
China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet

Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?

Feb 21
Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?

Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

Dec 07
Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate

Nov 10
China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate

These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

Aug 29
These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?

Aug 03
Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?

Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?

May 03
Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?

Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?

Apr 12
Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?

Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Mar 17
Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

An Intrinsic Calculation For China Resources Pharmaceutical Group Limited (HKG:3320) Suggests It's 24% Undervalued

Feb 14
An Intrinsic Calculation For China Resources Pharmaceutical Group Limited (HKG:3320) Suggests It's 24% Undervalued

If You Had Bought China Resources Pharmaceutical Group's (HKG:3320) Shares Three Years Ago You Would Be Down 63%

Jan 17
If You Had Bought China Resources Pharmaceutical Group's (HKG:3320) Shares Three Years Ago You Would Be Down 63%

We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt

Nov 29
We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt

China Resources Pharmaceutical Group Limited (HKG:3320) Is About To Go Ex-Dividend, And It Pays A 2.5% Yield

Jun 25
China Resources Pharmaceutical Group Limited (HKG:3320) Is About To Go Ex-Dividend, And It Pays A 2.5% Yield

Shareholder Returns

3320HK PharmaceuticalsHK Market
7D-0.6%6.5%1.6%
1Y-25.1%-11.9%-12.3%

Return vs Industry: 3320 underperformed the Hong Kong Pharmaceuticals industry which returned -11.9% over the past year.

Return vs Market: 3320 underperformed the Hong Kong Market which returned -12.3% over the past year.

Price Volatility

Is 3320's price volatile compared to industry and market?
3320 volatility
3320 Average Weekly Movement6.0%
Pharmaceuticals Industry Average Movement6.4%
Market Average Movement7.3%
10% most volatile stocks in HK Market14.5%
10% least volatile stocks in HK Market3.5%

Stable Share Price: 3320 has not had significant price volatility in the past 3 months.

Volatility Over Time: 3320's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200771,000Xiaosong Baihttps://www.crpharm.com

China Resources Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and Hong Kong. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biopharmaceutical drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular, alimentary tract, metabolism and endocrine, respiratory, orthopedics, oncology, medical nutrition, gastroenterology, pediatrics, genitourinary system, cough and cold, anti-infection, dermatology, infusion solutions, etc. It also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies.

China Resources Pharmaceutical Group Limited Fundamentals Summary

How do China Resources Pharmaceutical Group's earnings and revenue compare to its market cap?
3320 fundamental statistics
Market capHK$32.42b
Earnings (TTM)HK$4.16b
Revenue (TTM)HK$267.33b

7.8x

P/E Ratio

0.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
3320 income statement (TTM)
RevenueHK$267.33b
Cost of RevenueHK$225.69b
Gross ProfitHK$41.64b
Other ExpensesHK$37.48b
EarningsHK$4.16b

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

Mar 26, 2024

Earnings per share (EPS)0.66
Gross Margin15.58%
Net Profit Margin1.56%
Debt/Equity Ratio81.3%

How did 3320 perform over the long term?

See historical performance and comparison

Dividends

3.1%

Current Dividend Yield

24%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.